Potential Role of Dipeptidyl Peptidase-4 in Regulating Mitochondria and Oxidative Stress in Cardiomyocytes

被引:1
|
作者
Lee, Shih-Yi [1 ,2 ]
Wu, Shao-Tung [3 ]
Du, Chen-Xuan [3 ]
Ku, Hui-Chun [3 ]
机构
[1] MacKay Mem Hosp, Div Pulm & Crit Care Med, Taipei, Taiwan
[2] MacKay Jr Coll Med Nursing & Management, Taipei, Taiwan
[3] Fu Jen Catholic Univ, Dept Life Sci, 510,Zhongzheng Rd, New Taipei City 242, Taiwan
关键词
DPP4; Oxidative stress; Mitochondria; Nrf2; PGC-1; alpha; GAMMA COACTIVATOR 1-ALPHA; HEART-FAILURE; MOLECULAR-MECHANISMS; DPP-4; INHIBITORS; SKELETAL-MUSCLE; OXYGEN; SITAGLIPTIN; BIOGENESIS; LINAGLIPTIN; PROTECTS;
D O I
10.1007/s12012-024-09884-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oxidative stress causes mitochondrial damage and bioenergetic dysfunction and inhibits adenosine triphosphate production, contributing to the pathogenesis of cardiac diseases. Dipeptidyl peptidase 4 (DPP4) is primarily a membrane-bound extracellular peptidase that cleaves Xaa-Pro or Xaa-Ala dipeptides from the N terminus of polypeptides. DPP4 inhibitors have been used in patients with diabetes and heart failure; however, they have led to inconsistent results. Although the enzymatic properties of DPP4 have been well studied, the substrate-independent functions of DPP4 have not. In the present study, we knocked down DPP4 in cultured cardiomyocytes to exclude the effects of differential alteration in the substrates and metabolites of DPP4 then compared the response between the knocked-down and wild-type cardiomyocytes during exposure to oxidative stress. H2O2 exposure induced DPP4 expression in both types of cardiomyocytes. However, knocking down DPP4 substantially reduced the loss of cell viability by preserving mitochondrial bioenergy, reducing intracellular reactive oxygen species production, and reducing apoptosis-associated protein expression. These findings demonstrate that inhibiting DPP4 improves the body's defense against oxidative stress by enhancing Nrf2 and PGC-1 alpha signaling and increasing superoxide dismutase and catalase activity. Our results indicate that DPP4 mediates the body's response to oxidative stress in individuals with heart disease.
引用
收藏
页码:1090 / 1104
页数:15
相关论文
共 50 条
  • [31] Dipeptidyl peptidase-4 inhibition prevents lung injury in mice under chronic stress via the modulation of oxidative stress and inflammation
    Zhang, Shengming
    Li, Ping
    Xin, Minglong
    Jin, Xianglan
    Zhao, Longguo
    Nan, Yongshan
    Cheng, Xian Wu
    EXPERIMENTAL ANIMALS, 2021, 70 (04) : 541 - 552
  • [32] Integrated Protocol to Design Potential Inhibitors of Dipeptidyl Peptidase-4 (DPP-4)
    Pantaleao, Simone Queiroz
    Philot, Eric Allison
    Almeida, Michell de Oliveira
    Lima, Angelica Nakagawa
    de Sairre, Mirela Ines
    Scott, Ana Ligia
    Honorio, Kathia Maria
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2020, 20 (03) : 209 - 226
  • [33] CD26/Dipeptidyl Peptidase-4 as a Potential Biomarker in Pulmonary Sarcoidosis
    Yoshioka, K.
    Kawasaki, T.
    Hatano, R.
    Sakayori, M.
    Abe, M.
    Morimoto, C.
    Tatsumi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [34] Critical Role for Dipeptidyl Peptidase-4 Activity in the Pathogenesis of Experimental Autoimmune Myocarditis
    Maejima, Yasuhiro
    Ito, Yusuke
    Tamura, Natsuko
    Isobe, Mitsuaki
    CIRCULATION RESEARCH, 2016, 119
  • [35] Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
    Sebastian-Martin, Alba
    Sanchez, Belen G.
    Mora-Rodriguez, Jose M.
    Bort, Alicia
    Diaz-Laviada, Ines
    BIOMEDICINES, 2022, 10 (08)
  • [36] Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
    Richter, Bernd
    Bandeira-Echtler, Elizabeth
    Bergerhoff, Karla
    Lerch, Christian
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (04) : 753 - 768
  • [37] Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
    Saisho, Y.
    Itoh, H.
    DIABETIC MEDICINE, 2013, 30 (04) : e149 - e150
  • [38] Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
    Rankovic, Marina
    Jeremic, Nevena
    Srejovic, Ivan
    Radonjic, Katarina
    Stojanovic, Aleksandra
    Glisic, Milos
    Bolevich, Stefani
    Bolevich, Sergey
    Jakovljevic, Vladimir
    HEART FAILURE REVIEWS, 2021, 26 (02) : 437 - 450
  • [39] Clinical Utility of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin
    Grunberger, George
    POSTGRADUATE MEDICINE, 2013, 125 (03) : 79 - 90
  • [40] Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
    Makino, Yuichi
    Fujita, Yukihiro
    Haneda, Masakazu
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2015, 24 (01): : 67 - 73